News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
332,599 Results
Type
Article (18051)
Company Profile (312)
Press Release (314229)
Multimedia
Podcasts (90)
Webinars (12)
Section
Business (95509)
Career Advice (224)
Deals (16847)
Drug Delivery (49)
Drug Development (57342)
Employer Resources (41)
FDA (6853)
Job Trends (6469)
News (171591)
Policy (12005)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (2)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (2)
Academia (1003)
Accelerated approval (24)
Adcomms (14)
Allergies (95)
Alliances (24659)
ALS (145)
Alzheimer's disease (1176)
Antibody-drug conjugate (ADC) (289)
Approvals (7112)
Artificial intelligence (315)
Autoimmune disease (149)
Automation (10)
Bankruptcy (121)
Best Places to Work (5559)
BIOSECURE Act (7)
Biosimilars (135)
Biotechnology (238)
Bladder cancer (117)
Brain cancer (51)
Breast cancer (412)
Cancer (3711)
Cardiovascular disease (285)
Career advice (206)
Career pathing (11)
CAR-T (255)
CDC (8)
Cell therapy (656)
Cervical cancer (20)
Clinical research (49772)
Collaboration (1330)
Company closure (3)
Compensation (784)
Complete response letters (45)
COVID-19 (1249)
CRISPR (95)
C-suite (664)
Cystic fibrosis (131)
Data (5060)
Decentralized trials (1)
Denatured (16)
Depression (109)
Diabetes (302)
Diagnostics (2126)
Digital health (16)
Diversity (6)
Diversity, equity & inclusion (10)
Drug discovery (224)
Drug pricing (62)
Drug shortages (5)
Duchenne muscular dystrophy (234)
Earnings (40725)
Editorial (30)
Employer branding (8)
Employer resources (39)
Events (61321)
Executive appointments (698)
FDA (8945)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (11)
Frontotemporal dementia (24)
Funding (1127)
Gene editing (206)
Generative AI (28)
Gene therapy (553)
GLP-1 (649)
Government (1318)
Grass and pollen (3)
Guidances (224)
Healthcare (7752)
HIV (40)
Huntington's disease (48)
IgA nephropathy (85)
Immunology and inflammation (228)
Immuno-oncology (54)
Indications (88)
Infectious disease (1414)
Inflammatory bowel disease (171)
Inflation Reduction Act (10)
Influenza (64)
Intellectual property (194)
Interviews (24)
IPO (9050)
IRA (22)
Job creations (1229)
Job search strategy (176)
JPM (51)
Kidney cancer (10)
Labor market (30)
Layoffs (364)
Leadership (15)
Legal (1738)
Liver cancer (58)
Longevity (13)
Lung cancer (502)
Lymphoma (306)
Machine learning (29)
Management (11)
Manufacturing (464)
MASH (149)
Medical device (3241)
Medtech (3263)
Mergers & acquisitions (8555)
Metabolic disorders (895)
mRNA (134)
Multiple sclerosis (132)
NASH (14)
Neurodegenerative disease (272)
Neuropsychiatric disorders (85)
Neuroscience (2241)
Neurotech (1)
NextGen: Class of 2026 (2327)
Non-profit (992)
Now hiring (32)
Obesity (428)
Opinion (162)
Ovarian cancer (149)
Pain (119)
Pancreatic cancer (185)
Parkinson's disease (256)
Partnered (15)
Patents (369)
Patient recruitment (405)
Peanut (48)
People (30711)
Pharmaceutical (49)
Pharmacy benefit managers (8)
Phase 1 (17213)
Phase 2 (22965)
Phase 3 (15154)
Pipeline (4348)
Policy (113)
Postmarket research (960)
Preclinical (7106)
Press Release (32)
Prostate cancer (175)
Psychedelics (53)
Radiopharmaceuticals (279)
Rare diseases (755)
Real estate (1786)
Recruiting (18)
Regulatory (11825)
Reports (21)
Research institute (1064)
Resumes & cover letters (27)
Rett syndrome (25)
RNA editing (21)
RSV (37)
Schizophrenia (141)
Series A (209)
Series B (151)
Service/supplier (2)
Sickle cell disease (94)
Special edition (19)
Spinal muscular atrophy (128)
Sponsored (17)
Startups (2242)
State (1)
Stomach cancer (6)
Supply chain (41)
Tariffs (26)
The Weekly (73)
Vaccines (512)
Venture capital (79)
Weight loss (236)
Women's health (45)
Worklife (3)
Date
Today (153)
Last 7 days (575)
Last 30 days (1845)
Last 365 days (20990)
2026 (3192)
2025 (21182)
2024 (23712)
2023 (26007)
2022 (31456)
2021 (32380)
2020 (27256)
2019 (19206)
2018 (14147)
2017 (16684)
2016 (14150)
2015 (17049)
2014 (12164)
2013 (8702)
2012 (8919)
2011 (9166)
2010 (8903)
Location
Africa (203)
Alabama (70)
Alaska (2)
Arizona (85)
Arkansas (6)
Asia (21990)
Australia (3780)
California (8460)
Canada (2103)
China (922)
Colorado (268)
Connecticut (325)
Delaware (267)
Europe (48143)
Florida (1039)
Georgia (244)
Hawaii (2)
Idaho (19)
Illinois (457)
India (41)
Indiana (230)
Iowa (10)
Japan (329)
Kansas (82)
Kentucky (9)
Louisiana (9)
Maine (11)
Maryland (897)
Massachusetts (6524)
Michigan (128)
Minnesota (270)
Mississippi (3)
Missouri (44)
Montana (18)
Nebraska (6)
Nevada (48)
New Hampshire (21)
New Jersey (2147)
New Mexico (16)
New York (2127)
North Carolina (939)
North Dakota (6)
Northern California (4284)
Ohio (192)
Oklahoma (13)
Oregon (25)
Pennsylvania (1455)
Puerto Rico (12)
Rhode Island (27)
South America (281)
South Carolina (15)
Southern California (3263)
Tennessee (51)
Texas (1098)
United States (27771)
Utah (137)
Virginia (173)
Washington D.C. (44)
Washington State (653)
West Virginia (1)
Wisconsin (86)
Wyoming (1)
332,599 Results for "pipeline therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
pipeline
Lilly Axes 3 Therapies Amid Pipeline-in-a-Product Push for GLP-1
One of the assets shelved by Eli Lilly is a gene therapy for dementia, which it obtained in its $1.04-billion acquisition of Prevail Therapeutics in late 2020.
February 5, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Akebia Therapeutics Announces Corporate Updates and 2026 Pipeline Outlook
January 12, 2026
·
13 min read
Earnings
Merck Bats Away ‘Modest Growth’ Accusations, Touts Broad Pipeline
In its 2025 full year and fourth-quarter earnings call, Merck executives touted the merits of recent deals and what CEO Robert Davis called “probably the broadest and widest pipeline we’ve had in years.”
February 3, 2026
·
2 min read
·
Dan Samorodnitsky
Press Releases
Neumora Therapeutics Highlights 2026 Pipeline Strategy and Anticipated Upcoming Milestones
January 5, 2026
·
6 min read
Press Releases
Werewolf Therapeutics Announces Pipeline and Business Updates
December 19, 2025
·
10 min read
Press Releases
AMGEN ACQUIRES DARK BLUE THERAPEUTICS, BOLSTERING ONCOLOGY PIPELINE
January 7, 2026
·
8 min read
Earnings
Biogen’s ‘Bridge To Growth’ Cuts Through a Stacked Phase 3 Pipeline
With Biogen’s multiple sclerosis portfolio facing more generic pressure than ever, the company is eyeing a busy late-stage pipeline and hunting for deals to build its return to growth.
February 6, 2026
·
2 min read
·
Annalee Armstrong
Press Releases
Bicycle Therapeutics Announces Leadership Transitions for Next Phase of Innovation Across Oncology Pipeline
February 4, 2026
·
6 min read
Press Releases
Dyne Therapeutics Announces Upcoming Presentations Across Neuromuscular Pipeline at 2026 MDA Clinical & Scientific Conference
February 22, 2026
·
7 min read
Press Releases
Aprea Therapeutics Strengthens Global Patent Portfolio in DNA Damage Response (DDR) Cancer Therapeutics, Paving Way for Pipeline Growth
February 12, 2026
·
6 min read
1 of 33,260
Next
